Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
Trial status:Recruiting
Trial ID:
BNT314-01
NCT ID:
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting
Trial Details
The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer.
This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose (MTD) which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose (MAD) will be investigated.
Medical Condition
Trial Drug
Phase
Phase 1
Type
Interventional
Estimated Enrolment
103
Estimated Trial Date
Nov 2023 - Sep 2026
Trial Participant Requirements
Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
START Midwest
Grand Rapids, Michigan, United States, 49546
Status
Recruiting
Location
Carolina BioOncology Institute, LLC
Huntersville, North Carolina, United States, 28078
Status
Recruiting
Location
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Status
Recruiting
Location
GZA Ziekenhuizen
Antwerpen, Belgium, 2018
Status
Recruiting
Location
CHU de Liège
Liege, Belgium, 4000
Status
Recruiting
Location
Rigshospitalet
Copenhagen, Denmark, DK-2100
Status
Recruiting